Liang Wang

Trials

Studies that name Liang Wang as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:48 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07554482 · Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

  Beijing Tongren Hospital · not yet recruiting · Extranodal NK/T-cell Lymphoma · principal investigator
• Ph2
  NCT07523737 · Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

  Beijing Tongren Hospital · recruiting · Primary Central Nervous System Lymphoma (PCNSL), Diffuse Large B Cell Lymphoma (DLBCL) · principal investigator
• Ph1/Ph2
  NCT07525466 · Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

  Beijing Tongren Hospital · recruiting · Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH) · principal investigator
• Ph2
  NCT07461831 · CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma

  Beijing Tongren Hospital · completed · Large B-Cell Lymphoma (LBCL) · principal investigator
• Ph2
  NCT07441993 · Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL

  Institute of Hematology & Blood Diseases Hospital, China · recruiting · Marginal Zone Lymphoma · principal investigator
• Ph4
  NCT07355699 · Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

  Beijing Tongren Hospital · recruiting · Marginal Zone Lymphoma(MZL) · principal investigator
• Ph1/Ph2
  NCT06376721 · Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma

  Beijing Tongren Hospital · recruiting · Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type, T-lymphoblastic Lymphoma · principal investigator
• N/A
  NCT06356506 · A Study on Factors of Biochemical Response in Autoimmune Hepatitis

  Beijing Friendship Hospital · not yet recruiting · Autoimmune Hepatitis · principal investigator
• Ph2
  NCT06244368 · GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

  Institute of Hematology & Blood Diseases Hospital, China · recruiting · Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma · principal investigator
• N/A
  NCT05532345 · Discrimination of DILI and AIH by Artificial Intelligence

  Beijing Friendship Hospital · completed · Drug-induced Liver Injury, Autoimmune Hepatitis · principal investigator
• N/A
  NCT05060289 · A Prognostic Model for Drug-induced Liver Injury in China

  Beijing Friendship Hospital · recruiting · Drug-induced Liver Injury · principal investigator
• Ph2
  NCT04917250 · GPED for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma

  Beijing Tongren Hospital · unknown · Extranodal NK/T-cell Lymphoma · principal investigator
• Ph2
  NCT03181815 · Cladribine in Combination With CAG in Patients With Refractory/Relapsed Acute Myeloid Leukemia

  Sun Yat-sen University · unknown · Acute Myeloid Leukemia, Relapse Leukemia · principal investigator
• Ph2
  NCT02360501 · Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma

  Sun Yat-sen University · completed · Nasopharyngeal Neoplasms · principal investigator
• Ph4
  NCT02347878 · Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)

  Sun Yat-sen University · unknown · Leukemia, Lymphoma · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-11 23:48 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 14 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.